Urinary matrix metalloproteinase-8 and -9 activities in type 2 diabetic subjects: A marker of incipient diabetic nephropathy?

Clinical Biochemistry

Volumn 43, Issue 7-8, 2010, Pages 635-639

  van der Zijl, Nynke J ^a   Hanemaaijer, Roeland ^b   Tushuizen, Maarten E ^a   Schindhelm, Roger K ^c   Boerop, Jeannette ^a   Rustemeijer, Cees ^d   Bilo, Henk J ^c   Verheijen, Jan H ^b   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c ISALA HOSPITAL   (Netherlands)

^d AMSTELLAND HOSPITAL   (Netherlands)

Author keywords

Albuminuria; Diabetic nephropathy; MMP 2; MMP 8; MMP 9; Type 2 diabetes mellitus

Indexed keywords

GELATINASE B; GLUCOSE; HEMOGLOBIN A1C; NEUTROPHIL COLLAGENASE;

ADULT; AGE; AGED; ALBUMINURIA; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET RESTRICTION; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; URINE LEVEL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 77951206996     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.02.006     Document Type: Article

References (37)

1. Molitch M.E., DeFronzo R.A., Franz M.J., Keane W.F., Mogensen C.E., Parving H.H, et al. Nephropathy in diabetes. Diabetes Care 2004, 27(Suppl. 1):S79-S83.
2. MacIsaac R.J., Tsalamandris C., Panagiotopoulos S., Smith T.J., McNeil K.J., Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004, 27:195-200.
3. Mogensen C.E. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia 1999, 42:263-285.
4. Mason R.M., Wahab N.A. Extracellular matrix metabolism in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14:1358-1373.
5. Tabaei B.P., Al-Kassab A.S., Ilag L.L., Zawacki C.M., Herman W.H. Does microalbuminuria predict diabetic nephropathy?. Diabetes Care 2001, 24:1560-1566.
6. Catania J.M., Chen G., Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Renal. Physiol. 2007, 292:F905-F911.
7. Lenz O., Elliot S.J., Stetler-Stevenson W.G. Matrix metalloproteinases in renal development and disease. J. Am. Soc. Nephrol. 2000, 11:574-581.
8. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 2003, 200:448-464.
9. McLennan S.V., Kelly D.J., Cox A.J., Cao Z., Lyons J.G., Yue D.K., et al. Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 2002, 45:268-275.
10. Ronco P., Chatziantoniou C. Matrix metalloproteinases and matrix receptors in progression and reversal of kidney disease: therapeutic perspectives. Kidney Int. 2008, 74:873-878.
11. Maeda S., Haneda M., Guo B., Koya D., Hayashi K., Sugimoto T., et al. Dinucleotide repeat polymorphism of matrix metalloproteinase-9 gene is associated with diabetic nephropathy. Kidney Int. 2001, 60:1428-1434.
12. McLennan S.V., Martell S.K., Yue D.K. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002, 51:2612-2618.
13. Tashiro K., Koyanagi I., Ohara I., Ito T., Saitoh A., Horikoshi S., et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 2004, 18:206-210.
14. Bai Y., Wang L., Li Y., Liu S., Li J., Wang H., et al. High ambient glucose levels modulates the production of MMP-9 and alpha5(IV) collagen by cultured podocytes. Cell. Physiol. Biochem. 2006, 17:57-68.
15. Death A.K., Fisher E.J., McGrath K.C., Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 2003, 168:263-269.
16. McLennan S.V., Fisher E., Martell S.Y., Death A.K., Williams P.F., Lyons J.G., et al. Effects of glucose on matrix metalloproteinase and plasmin activities in mesangial cells: possible role in diabetic nephropathy. Kidney Int. 2000, 77:S81-S87.
17. Ebihara I., Nakamura T., Shimada N., Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am. J. Kidney Dis. 1998, 32:544-550.
18. Diamant M., Hanemaaijer R., Verheijen J.H., Smit J.W., Radder J.K., Lemkes H.H. Elevated matrix metalloproteinase-2 and -9 in urine, but not in serum, are markers of type 1 diabetic nephropathy. Diabet. Med. 2001, 18:423-424.
19. Lauhio A., Sorsa T., Srinivas R., Stenman M., Tervahartiala T., Stenman U.H., et al. Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in. patients. with. diabetic. nephropathy. Ann. Med. 2008, 40:312-320.
20. Thrailkill K.M., Bunn R.C., Moreau C.S., Cockrell G.E., Simpson P.M., Coleman H.N., et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007, 30:2321-2326.
21. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia, Report of a WHO/IDF Consultation 2006, World Health Organization.
22. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008, 31(Suppl. 1):S55-S60. American Diabetes Association.
23. Hanemaaijer R., Visser H., Konttinen Y.T., Koolwijk P., Verheijen J.H. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol. 1998, 17:657-665.
24. Rigalleau V., Lasseur C., Perlemoine C., Barthe N., Raffaitin C., Liu C., et al. Estimation of glomerular filtration rate in diabetic subjects. Diabetes Care 2005, 28:838-843.
25. Caramori M.L., Fioretto P., Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient?. Diabetes 2000, 49:1399-1408.
26. Ritz E. Nephropathy in type 2 diabetes. J. Intern. Med. 1999, 245:111-126.
27. Nakamura T., Fukui M., Ebihara I., Osada S., Tomino Y., Koide H. Abnormal gene expression of matrix metalloproteinases and their inhibitor in glomeruli from diabetic rats. Ren. Physiol. Biochem. 1994, 17:316-325.
28. Del Prete D., Anglani F., Forino M., Ceol M., Fioretto P., Nosadini R., et al. Down-regulation of glomerular matrix metalloproteinase-2 gene in human NIDDM. Diabetologia 1997, 40:1449-1454.
29. Tomino Y., Suzuki S., Azushima C., Shou I., Ijima T., Yagame M., et al. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy. J. Clin. Lab. Anal. 2001, 15:188-192.
30. Cherney D.Z., Sochett E.B., Miller J.A. Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. Kidney Int. 2005, 68:1722-1728.
31. Rossing P., Rossing K., Gaede P., Pedersen O., Parving H.H. Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy. Diabetes Care 2006, 29:1024-1030.
32. Premaratne E., MacIsaac R.J., Tsalamandris C., Panagiotopoulos S., Smith T., Jerums G. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate. Diabetologia 2005, 48:2486-2493.
33. Nakamura T., Takahashi T., Fukui M., Ebihara I., Osada S., Tomino Y., et al. Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats. J. Am. Soc. Nephrol. 1995, 5:1492-1497.
34. Shoji T., Emoto M., Kawagishi T., Kimoto E., Yamada A., Tabata T., et al. Atherogenic lipoprotein changes in diabetic nephropathy. Atherosclerosis 2001, 156:425-433.
35. Chen H., Guh J., Chang J., Hsieh M., Shin S., Lai Y Role of lipid control in diabetic nephropathy. Kidney Int. 2005, 94:S60-S62.
36. Mohammadi-Karakani A., Sgharzadeh-Haghighi S., Ghazi-Khansari M., Hosseini R. Determination of urinary enzymes as a marker of early renal damage in diabetic patients. J. Clin. Lab. Anal. 2007, 21:413-417.
37. Uslu S., Efe B., Alatas O., Kebapci N., Colak O., Demirustu C., et al. Serum cystatin C and urinary enzymes as screening markers of renal dysfunction in diabetic patients. J. Nephrol. 2005, 18:559-567.